Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27873687 | 0.81 | CFB (0.40) | BRD4 | |
| SCHEMBL19418758 | 0.77 | ACHE (0.39) | BRD4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL25648828 | 0.76 | HSD17B10 (0.39) | BRD4NSD2CASP6 | |
| SCHEMBL30403479 | 0.76 | P2RX7 (0.40) | BRD4P2RX7TUBB4ATUBBTUBA3C | |
| SCHEMBL1013714 | 0.75 | NR3C1 (0.40) | BRD4P2RX7NR3C1PGRRHEB | |
| SCHEMBL24786395 | 0.74 | TNF (0.43) | P2RX7CSNK2A1 | |
| SCHEMBL27185263 | 0.73 | BRD4 (0.39) | BRD4AMY1AP2RX7NR3C1PGR | |
| SCHEMBL20576807 | 0.73 | BRD4 (0.39) | BRD4P2RX7PDE3BPDE3A | |
| SCHEMBL35212606 | 0.73 | TNF (0.40) | BRD4AMY1AP2RX7TUBB4ATUBB | |
| SCHEMBL12422267 | 0.72 | P2RX7 (0.36) | BRD4P2RX7NR3C1PGRRHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360103-A1 | COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2024-10-31 | — | — | US | disclosed |
| WO-2023278698-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360103-A1 | COMPLEMENT INHIBITION | C5, C9, C1QBP | BRD4 3214/4885NSD2 3824/4885CASP6 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.